Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
Ralph Francescone
Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
Tiffany Luong
Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
Neelima Shah
Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
Raj Madhani
Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
Gil Cukierman
Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
Essel Dulaimi
Department of Pathology, Fox Chase Cancer Center, Philadelphia, United States
Karthik Devarajan
Department of Cancer Epigenetics, Fox Chase Cancer Center, Philadelphia, United States
Brian L Egleston
Department of Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, United States
Emmanuelle Nicolas
Programs in Genomics, Fox Chase Cancer Center, Philadelphia, United States
R Katherine Alpaugh
Protocol Support Lab, Fox Chase Cancer Center, Philadelphia, United States
Ruchi Malik
Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States
Robert G Uzzo
Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, United States
John P Hoffman
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, United States
Erica A Golemis
Department of Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, United States
Desmoplasia, a fibrotic mass including cancer-associated fibroblasts (CAFs) and self-sustaining extracellular matrix (D-ECM), is a puzzling feature of pancreatic ductal adenocarcinoma (PDACs). Conflicting studies have identified tumor-restricting and tumor-promoting roles of PDAC-associated desmoplasia, suggesting that individual CAF/D-ECM protein constituents have distinguishable tumorigenic and tumor-repressive functions. Using 3D culture of normal pancreatic versus PDAC-associated human fibroblasts, we identified a CAF/D-ECM phenotype that correlates with improved patient outcomes, and that includes CAFs enriched in plasma membrane-localized, active α5β1-integrin. Mechanistically, we established that TGFβ is required for D-ECM production but dispensable for D-ECM-induced naïve fibroblast-to-CAF activation, which depends on αvβ5-integrin redistribution of pFAK-independent active α5β1-integrin to assorted endosomes. Importantly, the development of a simultaneous multi-channel immunofluorescence approach and new algorithms for computational batch-analysis and their application to a human PDAC panel, indicated that stromal localization and levels of active SMAD2/3 and α5β1-integrin distinguish patient-protective from patient-detrimental desmoplasia and foretell tumor recurrences, suggesting a useful new prognostic tool.